Genomics England will relocate its headquarters this autumn to One Canada Square, E14, to join the UK’s developing life sciences community.
The move comes amid plans revealed by Canary Wharf Group and Kadans to build a 750,000 sq ft commercial laboratory building – the largest in Europe.
Chris Wigley, chief executive of Genomics, said: “Genomics England is delivering an ambitious agenda, in partnership with the NHS and others, that will ensure the UK continues to lead the world in genomics.
“The move to Canary Wharf will enable us to deliver this agenda more effectively, benefitting our workforce as well as moving us to a more modern estate in close proximity to our partners in the NHS and life sciences sector.”
Canary Wharf is already home to a number of leading healthcare and life sciences-focused organisations, including Barts Health NHS Trust, the Medicines and Healthcare Products Regulatory Agency, Medical Defence Union, General Pharmaceutical Council and NHS Transformation.
Shobi Khan, chief executive of Canary Wharf Group, said: “Attracting a cluster of innovative companies to Canary Wharf, in advance of opening our purpose-built, laboratory-enabled space at North Quay, is part of our strategy to make Canary Wharf one of the UK’s leading centres for life sciences.”
CWG was advised by CBRE and JLL. SHB Real Estate acted for Genomics.
To send feedback, e-mail evelina.grecenko@eg.co.uk or tweet @gre_eve
Compare and explore the market in Canary Wharf >>
